What is the target price for Systemax stock?
Apr 11, 2022 · On average, they expect Systemax's stock price to reach $44.00 in the next year. View analysts' price targets for Systemax or view top-rated stocks among Wall Street analysts . Who are Systemax's key executives?
What is Systemax's ticker symbol?
New York Stock Exchange SYX $32.15 -$0.29 -0.9% Price as of April 14, 2022, 4:00 p.m. ET View Interactive SYX Charts A direct marketer of brand name and private label products. The …
What is the upside from Systemax's current price?
The grants consisted of stock options to purchase an aggregate of 28,000 shares of SCYNEXIS common stock at a per share exercise price of $4.18, the closing trading price on Febr. GlobeNewswire.
Does Systemax boast high insider ownership?
Systemax Inc. (SYX): $35.16 1.20 (+3.53%) POWR Rating Component Grades Sign Up to See Ratings...FREE! We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now. Just click the link above. Growth S Value I Momentum G Stability N Sentiment U Quality P Add SYX to Watchlist Sign Up
Is Systemax a buy right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Systemax in the last year. There are currently 1 buy rating for the stock....
How were Systemax's earnings last quarter?
Systemax Inc. (NYSE:SYX) released its quarterly earnings data on Tuesday, May, 4th. The company reported $0.14 earnings per share for the quarter,...
How often does Systemax pay dividends? What is the dividend yield for Systemax?
Systemax declared a quarterly dividend on Monday, May 3rd. Shareholders of record on Monday, May 17th will be paid a dividend of $0.16 per share on...
Is Systemax a good dividend stock?
Systemax pays an annual dividend of $0.64 per share and currently has a dividend yield of 1.82%. The dividend payout ratio of Systemax is 38.10%. T...
What price target have analysts set for SYX?
1 analysts have issued 1-year price objectives for Systemax's shares. Their forecasts range from $44.00 to $44.00. On average, they anticipate Syst...
Who are Systemax's key executives?
Systemax's management team includes the following people: Mr. Richard Leeds , Exec. Chairman (Age 61, Pay $980k) Mr. Barry Litwin , CEO & Direc...
What is Barry Litwin's approval rating as Systemax's CEO?
8 employees have rated Systemax CEO Barry Litwin on Glassdoor.com . Barry Litwin has an approval rating of 57% among Systemax's employees. This pu...
Who are some of Systemax's key competitors?
Some companies that are related to Systemax include MSC Industrial Direct (MSM) , Global Industrial (GIC) , MRC Global (MRC) , DXP Enterprises...
What other stocks do shareholders of Systemax own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Systemax investors own include NVIDIA (NVDA) , EOG Resour...
How much is Net Loss 2021?
How much is the first quarter of 2021?
Net loss for the three months ended March 31, 2021 was $4.7 million, or ($0.18) per basic and ($0.23) per diluted share, compared to a net loss of $7.0 million, or ($0.72) per basic and diluted share for the three months ended March 31, 2020.
What is Crestone AWG?
Subsequent cash injections will be available upon achieving certain milestones. First Quarter 2021 Financial Results Cash and cash equivalents totaled $92.0 million on March 31, 2021, compared to $93.0 million in cash and cash equivalents on December 31, 2020.
What is ibrexafungerp?
Crestone Joins Antimicrobials Working Group. The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations.
Is Brexafemme an oral antifungal?
About Ibrexafungerp Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Component Grades
BREXAFEMME® (ibrexafungerp tablets), for oral use A novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 yearsCommercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET JERSEY CITY,
SYX POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
SYX Stock Summary
SYX scores best on the Quality dimension, with a Quality rank ahead of 96.97% of US stocks.
SYX Valuation Summary
The capital turnover (annual revenue relative to shareholder's equity) for SYX is 8.97 -- better than 96.52% of US stocks.
Latest SYX News From Around the Web
In comparison to the median Industrials stock, SYX's price/earnings ratio is 42.76% lower, now standing at 17.4.
Continue Researching SYX
Below are the latest news stories about Systemax Inc that investors may wish to consider to help them evaluate SYX as an investment opportunity.
Systemax (NYSE:SYX) Price Target and Consensus Rating
Want to do more research on Systemax Inc's stock and its price? Try the links below:
Systemax (NYSE:SYX) Consensus Price Target History
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Systemax Inc. (SYX)
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
About Price
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
